Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galena Left To Hope Review Of Trial Operations Rescues NeuVax

Executive Summary

Cancer vaccine development is a tricky undertaking, but Galena may be grasping at last straws with a third-party review of a recently halted study of NeuVax, hoping to discover operational reasons for cancer vaccine's poor performance.

You may also be interested in...



Sellas Will Take Increasingly Good Results With NeuVax Into FDA Discussions

Preparing to meet with FDA in December to plan next steps for NeuVax in triple-negative breast cancer, Sellas reveals 26-month data that show further clinical benefit compared with a 19-month interim look. Firm still hopes to out-license the vaccine candidate.

Phase II Study Opens Window For Sellas' NeuVax In Triple-Negative Breast Cancer

Sellas is pursuing accelerated approval for NeuVax in triple-negative breast cancer based on Phase II data, but that may be a tough sell with the FDA.

Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'

Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel